JP2015533833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533833A5 JP2015533833A5 JP2015536909A JP2015536909A JP2015533833A5 JP 2015533833 A5 JP2015533833 A5 JP 2015533833A5 JP 2015536909 A JP2015536909 A JP 2015536909A JP 2015536909 A JP2015536909 A JP 2015536909A JP 2015533833 A5 JP2015533833 A5 JP 2015533833A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- group
- lys
- peptide dimer
- asp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 56
- 239000000539 dimer Substances 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000005647 linker group Chemical group 0.000 claims description 31
- 150000008574 D-amino acids Chemical class 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 19
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 12
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 8
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 claims description 6
- -1 His Chemical group 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000008827 biological function Effects 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 5
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 239000002702 enteric coating Substances 0.000 claims description 4
- 238000009505 enteric coating Methods 0.000 claims description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 4
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 2
- IEXKUCOGQITOPO-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEXKUCOGQITOPO-UHFFFAOYSA-N 0.000 claims description 2
- GDYYIJNDPMFMTB-UHFFFAOYSA-N 2-[3-(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(CC(O)=O)=C1 GDYYIJNDPMFMTB-UHFFFAOYSA-N 0.000 claims description 2
- SLWIPPZWFZGHEU-UHFFFAOYSA-N 2-[4-(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(CC(O)=O)C=C1 SLWIPPZWFZGHEU-UHFFFAOYSA-N 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- NCFSMLBHQUAMHH-UHFFFAOYSA-N C1=CN=NN=C1.CC(C)(C)OC(=O)C1=C(C(O)=O)C=CC=C1C(O)=O Chemical compound C1=CN=NN=C1.CC(C)(C)OC(=O)C1=C(C(O)=O)C=CC=C1C(O)=O NCFSMLBHQUAMHH-UHFFFAOYSA-N 0.000 claims description 2
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 206010062164 Seronegative arthritis Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 230000003872 anastomosis Effects 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 125000006267 biphenyl group Chemical group 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000003167 cholangitis Diseases 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 208000023819 chronic asthma Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000017760 chronic graft versus host disease Diseases 0.000 claims description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- WRZXKWFJEFFURH-UHFFFAOYSA-N dodecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WRZXKWFJEFFURH-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 208000037902 enteropathy Diseases 0.000 claims description 2
- 230000002349 favourable effect Effects 0.000 claims description 2
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000004396 mastitis Diseases 0.000 claims description 2
- 208000008275 microscopic colitis Diseases 0.000 claims description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 2
- 238000002663 nebulization Methods 0.000 claims description 2
- 230000003256 osteocytic effect Effects 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 229940122065 Alpha4beta7 integrin antagonist Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- QFGCFKJIPBRJGM-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxy]-12-oxododecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCC(O)=O QFGCFKJIPBRJGM-UHFFFAOYSA-N 0.000 description 1
- 206010017969 Gastrointestinal inflammatory conditions Diseases 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712722P | 2012-10-11 | 2012-10-11 | |
| US61/712,722 | 2012-10-11 | ||
| US201361807714P | 2013-04-02 | 2013-04-02 | |
| US61/807,714 | 2013-04-02 | ||
| US14/050,349 US9273093B2 (en) | 2012-10-11 | 2013-10-10 | α4β7 peptide dimer antagonists |
| US14/050,349 | 2013-10-10 | ||
| PCT/US2013/064439 WO2014059213A1 (en) | 2012-10-11 | 2013-10-11 | NOVEL α4ß7 PEPTIDE DIMER ANTAGONISTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018191587A Division JP2019001825A (ja) | 2012-10-11 | 2018-10-10 | 新規なα４β７ペプチド二量体拮抗薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533833A JP2015533833A (ja) | 2015-11-26 |
| JP2015533833A5 true JP2015533833A5 (OSRAM) | 2016-12-01 |
| JP6480865B2 JP6480865B2 (ja) | 2019-03-13 |
Family
ID=50477907
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536909A Active JP6480865B2 (ja) | 2012-10-11 | 2013-10-11 | 新規なα４β７ペプチド二量体拮抗薬 |
| JP2018191587A Pending JP2019001825A (ja) | 2012-10-11 | 2018-10-10 | 新規なα４β７ペプチド二量体拮抗薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018191587A Pending JP2019001825A (ja) | 2012-10-11 | 2018-10-10 | 新規なα４β７ペプチド二量体拮抗薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9273093B2 (OSRAM) |
| EP (1) | EP2906584B1 (OSRAM) |
| JP (2) | JP6480865B2 (OSRAM) |
| KR (1) | KR20150084808A (OSRAM) |
| CN (1) | CN105102470A (OSRAM) |
| AU (2) | AU2013329135B2 (OSRAM) |
| CA (1) | CA2888479A1 (OSRAM) |
| HK (1) | HK1213583A1 (OSRAM) |
| IL (1) | IL238123A0 (OSRAM) |
| IN (1) | IN2015DN03039A (OSRAM) |
| NZ (1) | NZ706909A (OSRAM) |
| SG (2) | SG11201502812WA (OSRAM) |
| WO (1) | WO2014059213A1 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| EP3721902A1 (en) | 2013-03-14 | 2020-10-14 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
| AU2014232954B2 (en) | 2013-03-15 | 2018-08-09 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses therof |
| US20140294901A1 (en) * | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide dimer antagonists |
| JP6822839B2 (ja) | 2013-09-13 | 2021-01-27 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、及びその組成物 |
| CN106456589B (zh) | 2013-12-18 | 2020-07-07 | 斯克利普斯研究所 | 修饰的治疗剂、订合的肽脂质缀合物及其组合物 |
| ES2890600T3 (es) | 2014-05-16 | 2022-01-20 | Protagonist Therapeutics Inc | Péptidos de tioéter antagonistas de integrina alfa4beta7 |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| CA2962642A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel .alpha.4.beta.7 peptide monomer and dimer antagonists |
| CN107921098A (zh) * | 2015-06-17 | 2018-04-17 | 加州生物医学研究所 | 修饰的治疗剂及其组合物 |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CN108348581B (zh) | 2015-09-04 | 2022-07-01 | 斯克利普斯研究所 | 胰岛素免疫球蛋白融合蛋白 |
| EP3365353B1 (en) | 2015-10-23 | 2023-11-22 | Universiteit Twente | Integrin binding peptides and uses thereof |
| CA3004714A1 (en) * | 2015-11-11 | 2017-05-18 | Encycle Therapeutics, Inc. | Fragment synthesis of cyclic peptides |
| DK3387019T3 (da) | 2015-12-09 | 2022-01-10 | Scripps Research Inst | Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| KR102891788B1 (ko) | 2016-02-04 | 2025-11-26 | 더 스크립스 리서치 인스티튜트 | 인간화 항-cd3 항체, 접합체 및 이의 용도 |
| US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
| EP3939989A1 (en) | 2016-11-11 | 2022-01-19 | Zealand Pharma A/S | Cyclic peptides multimers targeting alpha 4beta 7 integrin |
| KR20200015540A (ko) * | 2017-05-10 | 2020-02-12 | 인사이클 세라퓨틱스, 인코포레이티드 | α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드 |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| EP4501952A3 (en) | 2018-02-08 | 2025-04-16 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CN113631569A (zh) * | 2019-03-28 | 2021-11-09 | 领导医疗有限公司 | 用于合成β-高氨基酸的方法 |
| CN116082455A (zh) | 2019-07-10 | 2023-05-09 | 领导医疗有限公司 | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 |
| BR112022013628A2 (pt) * | 2020-01-10 | 2022-11-22 | Protagonist Therapeutics Inc | Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7 |
| WO2021146454A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| MA58373B1 (fr) | 2020-01-15 | 2025-07-31 | Janssen Biotech, Inc. | Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires |
| MX2023005994A (es) | 2020-11-20 | 2023-08-11 | Janssen Pharmaceutica Nv | Composiciones de inhibidores peptidicos del receptor de interleucina-23. |
| JP2024522196A (ja) | 2021-06-09 | 2024-06-11 | ザ スクリプス リサーチ インスティテュート | 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法 |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| US4724229A (en) * | 1986-09-30 | 1988-02-09 | Smithkline Beckman Corporation | Arg-arg-arg-vasopressin antagonists |
| AU666853B2 (en) * | 1991-04-05 | 1996-02-29 | Genentech Inc. | Platelet aggregation inhibitors having high specificity for GP IIbIIIa |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US5990084A (en) | 1996-04-19 | 1999-11-23 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
| JP2001509493A (ja) * | 1997-07-11 | 2001-07-24 | インナーダイン， インコーポレイテッド | 放射送達構造体の調製およびシール化のための方法およびシステム |
| US6818617B1 (en) | 1997-08-15 | 2004-11-16 | Temple University- Of The Commonwealth System Of Higher Education | EC-3, an inhibitor of α4β1 and α4β7 integrins |
| WO1999026615A1 (en) | 1997-11-24 | 1999-06-03 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
| EP1100473A2 (en) * | 1998-07-28 | 2001-05-23 | InnerDyne, Inc. | Absorbable brachytherapy and chemotherapy delivery devices and methods |
| AUPP616598A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Auxiliary for amide bond formation |
| AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
| AUPP660698A0 (en) | 1998-10-21 | 1998-11-12 | University Of Queensland, The | A method of protein engineering |
| BR0010599A (pt) | 1999-04-12 | 2002-02-13 | Aventis Pharma Ltd | Compostos de heteroarila bicìclicos substituìdos como antagonistas de integrina |
| AU2001262089A1 (en) | 2000-03-14 | 2001-09-24 | Novartis Ag | Alpha4beta1 and alpha4beta7 integrin inhibitors |
| DE10107707A1 (de) | 2001-02-19 | 2002-08-29 | Wilex Biotechnology Gmbh | Antagonisten für alpha¶4¶beta¶7¶-Integrin |
| AUPS039702A0 (en) | 2002-02-08 | 2002-03-07 | University Of Queensland, The | Common protein surface shapes and uses therefor |
| AU2003301059A1 (en) | 2002-12-18 | 2004-07-22 | Wyeth | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
| WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| SI1680443T1 (sl) | 2003-11-05 | 2014-01-31 | Dana-Farber Cancer Institute, Inc. | Stabilizirani peptidi z alfa vijačnico in uporabe le-teh |
| EP1695255B1 (en) | 2003-12-19 | 2016-09-07 | Applied Biosystems, LLC | Methods and systems for protein and peptide evidence assembly |
| PE20051053A1 (es) | 2004-01-09 | 2005-12-12 | Pfizer | ANTICUERPOS CONTRA MAdCAM |
| US8536140B2 (en) | 2004-03-12 | 2013-09-17 | Mti Meta Tech Inc. | Methods for treating inflammatory bowel disease |
| US20070197430A1 (en) | 2004-06-24 | 2007-08-23 | Jonathan Baell | Conjugates And Therapeutic Uses Thereof |
| WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| JP2008521840A (ja) | 2004-11-30 | 2008-06-26 | ガストロテック・ファルマ・アクティーゼルスカブ | 成長ホルモン分泌促進物質レセプター１ａリガンド |
| AU2007260787A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc | IL-17 and IL-23 antagonists and methods of using the same |
| EP2109480B1 (en) | 2006-12-07 | 2017-06-28 | The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services | Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| EP2392597B1 (en) | 2007-04-27 | 2014-04-02 | ZymoGenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| WO2009002947A2 (en) * | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| US20100190710A1 (en) | 2007-07-06 | 2010-07-29 | Valorisation Hsj, Societe En Commandite | Il-23 receptor antagonists and uses thereof |
| WO2009039185A1 (en) * | 2007-09-17 | 2009-03-26 | The Trustees Of Columbia University In The City Of New York | Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation |
| US20100280098A1 (en) | 2007-10-05 | 2010-11-04 | Juliano Rudolph L | Receptor targeted oligonucleotides |
| DE102009007381A1 (de) * | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
| US8999935B2 (en) | 2009-02-11 | 2015-04-07 | New York University | Treatment of osteoporosis in peri- and post-menopausal women with hepcidin |
| EP2418213B1 (en) * | 2009-04-08 | 2014-11-19 | Takeda Pharmaceutical Company Limited | Neuromedin u derivative |
| US10416172B2 (en) | 2010-03-31 | 2019-09-17 | Medical Diagnostic Laboratories, Llc | Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling |
| WO2012101599A2 (en) | 2011-01-27 | 2012-08-02 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
| US9169292B2 (en) | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| AU2012327226C1 (en) | 2011-12-09 | 2017-03-02 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
| US20150157692A1 (en) | 2012-05-23 | 2015-06-11 | The University Of Chicago | Methods of treating obesity |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| EP2956154A4 (en) | 2013-02-15 | 2016-07-27 | Srx Cardio Llc | TYPE 9 (PCSK9) PROPYTEIN CONVERTASE SUBTILISINE / KEXINE PROPAGINE CONVERTASE BINDING LIGANDS FOR USE IN MODULATION OF SERIES LEVELS OF LOW DENSITY LIPOPROTEIN (LDL) |
| US20140294901A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide dimer antagonists |
| US20140294902A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide antagonists |
| KR102247493B1 (ko) | 2013-06-24 | 2021-04-30 | 가부시키가이샤 캔버스 | 암 환자 하위집단을 위한 복합 용도 및 치료에서 펩티드 및 펩티드모방체 |
-
2013
- 2013-10-10 US US14/050,349 patent/US9273093B2/en active Active
- 2013-10-11 SG SG11201502812WA patent/SG11201502812WA/en unknown
- 2013-10-11 SG SG10201702979SA patent/SG10201702979SA/en unknown
- 2013-10-11 WO PCT/US2013/064439 patent/WO2014059213A1/en not_active Ceased
- 2013-10-11 IN IN3039DEN2015 patent/IN2015DN03039A/en unknown
- 2013-10-11 JP JP2015536909A patent/JP6480865B2/ja active Active
- 2013-10-11 NZ NZ706909A patent/NZ706909A/en unknown
- 2013-10-11 EP EP13845982.1A patent/EP2906584B1/en active Active
- 2013-10-11 AU AU2013329135A patent/AU2013329135B2/en active Active
- 2013-10-11 HK HK16101620.8A patent/HK1213583A1/zh unknown
- 2013-10-11 KR KR1020157011369A patent/KR20150084808A/ko not_active Ceased
- 2013-10-11 CA CA2888479A patent/CA2888479A1/en active Pending
- 2013-10-11 CN CN201380064713.8A patent/CN105102470A/zh active Pending
-
2015
- 2015-04-02 IL IL238123A patent/IL238123A0/en unknown
-
2016
- 2016-01-19 US US15/000,923 patent/US20160368966A1/en not_active Abandoned
-
2018
- 2018-03-06 AU AU2018201599A patent/AU2018201599A1/en not_active Abandoned
- 2018-10-10 JP JP2018191587A patent/JP2019001825A/ja active Pending
-
2019
- 2019-02-22 US US16/282,908 patent/US20190248870A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015533833A5 (OSRAM) | ||
| JP2016515620A5 (OSRAM) | ||
| JP2016518351A5 (OSRAM) | ||
| JP2017522362A5 (OSRAM) | ||
| JP6480865B2 (ja) | 新規なα４β７ペプチド二量体拮抗薬 | |
| JP2017535527A5 (OSRAM) | ||
| ES2655389T3 (es) | Compstatina modificada con esqueleto peptídico y modificaciones c-terminales | |
| AU747806B2 (en) | Kappa receptor opioid peptides | |
| US8748575B2 (en) | Therapeutic peptides | |
| JP6039553B2 (ja) | エンドモルフィンのμオピオイド受容体アゴニスト類似体 | |
| EP3294315A2 (en) | Novel short-chain peptides as kappa opioid receptors (kor) agonist | |
| RU2017114414A (ru) | НОВЫЕ АНТАГОНИСТЫ α4β7 НА ОСНОВЕ МОНОМЕРНЫХ И ДИМЕРНЫХ ПЕПТИДОВ | |
| JP2016515620A (ja) | 新規のα４β７ペプチド拮抗薬 | |
| JP6633523B2 (ja) | Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体 | |
| IL316406A (en) | Lipid-modified relaxin B peptide chains and their medical use | |
| CA2952475A1 (en) | Vip fragment for the treatment of myocardial fibrosis | |
| TW200819139A (en) | Novel analogs of vasoactive intestinal peptide | |
| JP2020055873A (ja) | 白血球動員をブロックするペプチドおよび使用方法 | |
| CN111247162B (zh) | 多黏菌素类似物及其制备方法 | |
| Sakura et al. | Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity | |
| US6596692B1 (en) | Substance P analogs for the treatment of cancer | |
| EP1198478B1 (en) | Somatostatin analogs and their use for the treatment of cancer | |
| AU2006301494A1 (en) | Antagonists against interaction of PF4 and RANTES | |
| CN105949278A (zh) | 一种取代的四氢呋喃水溶性衍生物及其应用 | |
| JPH09502427A (ja) | オキシトシン拮抗薬活性を示すペプチド |